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Oestradiol is mainly produced in the ovary and in addition is locally synthesised in the brain. Most of the
oestradiol functions have been associated with its capacity to directly bind and dimerize “classical oestrogen
receptors” (ERs), alpha and beta. The ERs' actions have been classiﬁed as “genomic” and “non-genomic”
depending on whether protein synthesis occurs through ER driven transcription or not. Indeed, recent evi-
dence suggests that oestrogen may also act as a more general “trophic factor”. Hence, we have studied the
capacity of oestradiol to activate the PI3K/Akt pathway and its implication in axonal growth and neuronal
morphogenesis. Our data show that when oestrogen receptors are blocked the axonal and dendritic lengths
are reduced in mouse primary neurons. We found that Akt/Rheb/mTORC1 responds to ER activation in neu-
rons and that some elements of this pathway are able to restore a normal neuronal morphology even in the
presence of oestrogen receptor antagonist. All these data demonstrate a new mechanism regulated by
oestradiol, at least in neuronal morphogenesis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Oestrogen receptors (ERs) fulﬁl a wide variety of functions in differ-
ent cell types and in neurons, participating in signalling pathways impli-
cated in survival, cytoskeletal rearrangement and synaptic transmission.
ERs are expressed as two classical isoforms, ERα and ERβ, although other
variants may be found. ERs are present in different neuronal domains
[1–3]. Indeed, oestrogen modulates dendritic arborisation in adult neu-
rons [4], spine density [5] and certain electrophysiological properties [6].
Several studies have deﬁned the local synthesis of oestradiol in the CNS,
in neurons and glia from regions such as the cortex and the hippocam-
pus. In physiological conditions, oestradiol is mainly synthesised by
glial cells, although it may also be produced by neurons, and its produc-
tionmay increase after neuronal damage [7]. Once oestradiol occupies its
ligand-binding domain, the ERs can act through distinct “genomic” and
“non-genomic” pathways. In the “genomic” pathway, ER is a nuclear fac-
tor that interacts with a speciﬁc DNA sequence called the “ERE site”, and
it activates the transcription. This activity ultimately modulates the syn-
thesis of newproteins. The recent description of different partners for the
ER in the nucleus, like AP-1/jun or TCFs [8], may increase the complexity
in gene expression.“Severo Ochoa”, CIBERNED-CSIC-
noma deMadrid, 28049Madrid,
ell).
l rights reserved.The “non-genomic” actions of ER involve interactions with intra-
cellular pathways, whereby the ligand–ER complex modulates the ac-
tivity of several kinases and structural proteins, such as PI3K–Akt–GSK3,
MAPK, or nuclearβ-catenin function. In contrast to the classical pathway,
these effects occur very rapidly (i.e.: changes in phosphorylation level),
such as in the modulation of the stability of the cytoskeleton or its com-
ponents in several cell models. Indeed, there is data indicating that
oestradiol activates the PI3K/Akt pathway through the ERs in a similar
way to other growth factors [9,10].
Hence, we have studied the capacity of oestradiol to activate the
PI3K/Akt/GSK3 pathway and its implication in axonal growth [11]. Spe-
ciﬁcally, we assessed the consequences of oestrogen receptor block on
neuronal morphology using a pharmacological approach. Our results
show that the axonal and dendritic lengths are reduced in hippocampal
neurons at early stages when oestrogen receptors are blocked in corre-
lation with a reduction on Akt and S6 phosphorylations. Therefore, we
centred our analysis on some Akt targets that are potentially dependent
on oestradiol and whose activity could rescue the loss of ER function.
Among these, we focused on the regulation of the GSK3-β-catenin
axis and the mTORC1 pathway [12,13], considering their implication
in neuronal morphology [14]. We found that Rheb/mTORC1 responds
to ER activation in neurons and that it is able to restore a normal mor-
phology to neurons even when axonal elongation is impaired by ER an-
tagonist. As a result of these studieswe have deﬁned a new role for both
ERs in neuronal differentiation, and for this activity the regulation of
Rheb/mTORC1–S6K pathway is essential.
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2.1. Neuroblastoma N2a cells, primary hippocampal and cortical neurons
2.1.1. Cell lines
Murine neuroblastoma N2a cells (ATCC-CCL131) or HEK 293T cells
(ATCC-CRL 11268) were grown at 37 °C in an atmosphere containing
7% CO2, in DMEM supplemented with 10% foetal bovine serum (FBS,
GIBCO) and 2 mM glutamine.
2.2. Primary cultures
Hippocampal or cortical neuronswere obtained from E17-18mouse
embryos basically as described previously [15]. Brieﬂy, after isolating
the embryonic hippocampi or cortex from 8 to 10 mice in Ca2+- and
Mg2+-free Hanks Buffer Salt Solution (HBSS 1×, GIBCO), the hippocam-
pi were incubated in 0.25% trypsin (GIBCO) and cortex in the same so-
lution plus 1 mg/ml DNAse-I (Roche) for 15 min at 37 °C. The trypsin
was then eliminated bywashing three times with HBSS 1×, and the tis-
sue triturated using two decreasing diameter Pasteur pipettes. The cells
were counted and plated in a poly-lysine (1 mg/ml, Sigma) coated
60 mm dish containing plating medium (MEM, 20% glucose, 10% horse
serum and antibiotics), and incubated for 3 h. After plating, the medium
was changed to phenol red-free NB medium supplemented with B27
(GIBCO) and the neurons were maintained under these conditions for
the time indicated in each experiment.
2.3. Treatments
17-β Oestradiol (50 nM, Sigma), ICI 182,780 (5 μM, Tocris) or
rapamycin (20 nM, Calbiochem) were added to the neuronal medium
from the moment of plating and maintained during the indicated days
in vitro (DIV), changing the medium each day until they were analysed.
The vehicle alone, either DMSO or ethanol, was added to the control
cells. To inhibit PI3K activity, LY294002 (Calbiochem) was used at a
ﬁnal concentration of 25 μM.
2.4. Western blotting and antibodies
Cell extracts were prepared in lysis buffer containing 200 mM Hepes
[pH 7.4], 100 mMNaCl, 100 mMNaF, 1 mMNa3VO4, 5 mMEDTA, 1% Tri-
ton and a protease inhibitor cocktail (Complete™, Roche) according to
the protocol described elsewhere [16]. Brieﬂy, the cells were left for
30 min on ice in lysis buffer and after adding a loading buffer; the samples
were boiled for 10 min and resolved by Tris/Glycine SDS-Polyacrylamide
gel electrophoresis. Subsequently, the proteins were transferred to a ni-
trocellulose membrane (Amersham) in the presence of 20% methanol
and 0.1% SDS, and non-speciﬁc signals were blocked by incubating the
membrane in PBS-Tween-20 (PBT) and 5% non-fat milk for 2 h.
The antibodies used to probe the membranes were raised against:
β-catenin 1:800 (Transduction Labs); Axin2 1:800 (Abcam); GSK3
α/β, GSKPSer9, 21, S6 Ribosomal protein, phospho-S235/236-S6Ribosomal
protein, phosphor-Thr308 Akt, phospho-Ser473-Akt, phospho-S65-4E-BP1,
total Akt and PThr389-p70 S6K (Cell Signalling Tech.); total p70 S6K
(Santa Cruz). The binding of these antibodies was then detected with
horseradish peroxidase conjugated secondary antibodies (Amersham)
used at a dilution of 1:5000.
2.5. Immunocytochemistry
Neurons were ﬁxed for 20 min at RT with 4% paraformaldehyde
and after 3 washes for 10 min in PBS; the ﬁxed-cells were incubated
with 50 mM NH4Cl, blocked and then permeabilised for 30 min with
1% FCS, 0.22% Gelatin (Gelatin from cold water ﬁsh skin, Sigma) and
0.1% Triton-X-100 in PBS. The cells were incubated with the primary
antibodies for 2 h at RT and after 3 washes with blocking solution,the secondary Alexa ﬂuor-488 or 594 antibodies were added (1:1000,
Molecular Probes). The primary antibodies used, were: mouse anti-
SMI31 (Covance) ormouse anti-Tau-1 (Chemicon), to label axonal com-
partment; and polyclonal anti-MAP2 (1:400, Sigma) to label somato-
dendritic compartment. In additionwe used rabbit anti-GFP (Invitrogen),
to establish the putative presence of glia, and tyrosinated tubulin (1:400,
Sigma) as a control. To visualise the distribution of polymerised actin,
ﬁxed cells were stained with Alexa 488 or 594 conjugated phalloidin as
indicated (1:100, Molecular Probes). Nuclei were stained with ToPro3
(Invitrogen), and the coverslips were mounted with Fluoromount G
(Southern Biotechnology Associates, Inc) and photographed on a confo-
cal microscope (LSM 510 META, Zeiss).
2.6. Nucleofection
Plasmids were introduced into cortical or hippocampal neurons by
nucleofection (Amaxa Basic Nucleofector Kit for Primary Mammalian
Neural cells, Lonza) according to the manufacturers' instructions. A
total of 3 μg of plasmid plus 1 μg GFP was introduced into 4×106 cells.
The nucleofection was performed in cell suspension before platting.
2.7. Expression plasmids
Mammalian expression vectors for the expression of RhebQ64L [17],
S6K1 wt (Sigma), β-catenin S33Y and wt β-catenin (provided by B.
Vogelstein), S6K1-HA wt, S6K1ΔCtE389 (Addgene) [18] pEGFP-N1
and pcDNA3.1 (Invitrogen)were introduced into the cells by electropo-
ration (Nucleofector, Lonza) or using lipofectAMINE 2000 (Invitrogen)
in the case of N2a neuroblastoma cells.
2.8. Data analysis
Axonal and dendritic lengths were measured using the NeuronJ
plug-in of the Image J software. The axonal length was determined,
at least, in 100 neurons for each condition, and the axon was identiﬁed
as a Tau-1 positive extension. All data represent the mean±s.e.m from
at least 3 independent experiments. The statistical analysis was
performed using the Paired T-test tool or ANOVA with appropriated
posthoc test, when needed (Sigma Plot software).
To determine neuronal complexity (total length plus axonal and den-
dritic branching) we used a Sholl analysis [19] with those neurons
GFP-positive cells (either empty-pCDNA3, or RhebQ64L, or S6K1wt or ac-
tive mutant S6K, in all cases co-transfected with GFP-construct). After
that the cells were ﬁxed and stained with axonal marker (either Tau-1
or SMI-31) and MAP2 for dendritic compartment (n=90–120 neurons).
The number of processes intersecting the Sholl rings (an indication of the
number of processes from the cell body) was determined for each exper-
imental condition, and themean and standarddeviation, of eachdetermi-
nation represented in the Supplementary Fig. 2. In addition the number of
axonal ramiﬁcation and numbers of dendrites were determined.
3. Results
3.1. The ER antagonist, ICI 182,780, reduces neuronal complexity and
blocks axonal growth in hippocampal neurons
In recent years, evidence has been accumulated that oestradiol in-
ﬂuences neural plasticity [7,20], modifying different processes like
neurite extension in cultured neurons [21–24] or the branching of
adult neurons [25], and affecting complex task performances [26].
There is also some data pointing to a negative effect of oestrogen on
the extension of neurites from different brain regions [27]. However,
while all these cellular processes seem to bemodulated via theoestrogen
receptor, the mechanisms involved remain unclear. Hence, we set out to
analyze the components of the signalling pathway that underlies the
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pocampal or cortical embryonic neuron cultures.
Daily addition of oestradiol (50 nM) increased the ﬁnal complexity
(deﬁned as the whole length of axon and dendrites). Oestradiol treat-
ment of hippocampal neurons, from the ﬁrst day in vitro (DIV) to 3
DIV, mainly increased axonal length (202.8±8.9 μm versus 178.1±A
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When we analysed the effect at 7 DIV, the difference oestradiol-
mediated was evident in axonal length (370±29 μm versus 335±
24 μm in control neurons, pb0.05, Fig. 1A) and not signiﬁcant in den-
dritic length (60±9 μm versus 57±8 μm in control neurons, Fig. 1B).N
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centage of neurons (statistically not-signiﬁcant) are lost when compared with vehicle.
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daily administration of the speciﬁc antagonist, ICI 182,780 (ICI), at a
ﬁnal concentration of 5 μM impaired the extension and diminished
the complexity of these processes (Fig. 1A, B). Indeed, axons, identiﬁed
by the Tau-1 axonal marker, were signiﬁcantly shorter following ICI
treatment at DIV 3, (115.5±5.6 μm versus 178.1±6.5 μm in control
neurons, pb0.001, Fig. 1A, B), and the same effect was observed in the
case of dendrites (19±3 μm versus 37±5.5 μm in control neurons,
pb0.001). At DIV 7 the differences were more apparent in both cases,
in axonal length (135±30 μm versus 335±24 μm in control neurons,
pb0.001) and in dendritic length (19±4 μm versus 57±8 μm in con-
trol neurons, pb0.001) (Fig. 1B).
ICI did not appear to produce any toxicity in our neurons after
3 days in vitro (data not shown), and only a slight reduction of neuronal
viability was seen after 7 days but not statistically signiﬁcant (Fig. 1C).
The effects of both oestradiol and ICI were observed in both hippocam-
pal and cortical neurons (data not shown). From this initial observation,
the subsequent experiments weremainly focused on axonal length as a
reporter of neuronal morphogenesis.3.2. Oestradiol augments Akt phosphorylation at Ser473 and Thr308 in
hippocampal neurons
To analyse the mechanisms activated by ERs that might inﬂuence
neuronal morphology in more detail, we assessed whether oestradiol-
mediated neuritogenesis might be modulated, at least in part, by
“non-genomic” pathways. It is well known that the ER interacts
with the insulin/PI3K pathway in several cell lines and in neurons
[28], and this pathway fulﬁls a central role in neuronal polarity
[29]. We previously demonstrated that oestradiol addition modiﬁed
Akt phosphorylation at short-term (minutes) [30]. Now we try to
identify whether at long-range treatment the ﬁnal phosphorylation
status of Akt/GSK3 would be modiﬁed by oestradiol.
Our data showed a ﬁnal increase of Akt activity, inferred from the
phosphorylation of two of its regulatory residues Thr308 and Ser473.
Moreover, the phosphorylation of these residues was maintained as
control, in the presence of the ER antagonist ICI 182,780 (Fig. 2A).B
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tion, when we blocked PI3K by using LY 294002, we obtained a
clear inhibition of axonal development (Fig. 2B), in accordance with
previous studies [11,31]. Thus, we assessed whether the addition of
oestradiol might overcome this inhibitory effect. Our data indicated
that the addition of oestradiol was not sufﬁcient to rescue the pheno-
type generated by PI3K inhibition (Fig. 2A), which suggests that this
pathway lies downstream of oestradiol.3.3. The over-expression of β-catenin does not reverse the effect of ICI
182,780
To determinewhich of the elements controlled by the PI3K/Akt path-
waymight support the axonal elongationmediated by oestradiol, we fo-
cused on two major routes triggered by PI3K: ﬁrst, Akt–GSK3 and its
regulation of β-catenin stability [32]; and secondly, the Akt/mTORC1
pathway. Therefore, we initially tried to establish whether β-catenin
inﬂuences oestradiol-mediated neuritogenesis, because we reported
that oestradiol stabilised this protein in neurons [10,30] and indeed,
β-catenin is thought to affect neuronal plasticity [33]. Hence, we over-
expressed β-catenin in neurons, either wild type or the active S33Y mu-
tant, and then exposed them to the ER antagonist ICI 182,780. As an in-
ternal control, the expression of β-catenin from both plasmids was
conﬁrmed by the expression levels in N2a cells in the case of β-catenin
wt (Fig. 3C, left panel); and through the product of aβ-catenin/TCF target
gene, Axin 2 [34–36] in the case of β-catenin S33Y (Fig. 3C, right panel).
When both constructs were transfected into hippocampal neurons,
the expression of wt-β-catenin slightly increased the axonal length
when compared to cells transfected with the empty vector at 5 DIV
(320±16 μm versus control 270±15, pb0.001)(Fig. 3A, B), whereas
the expression of the active formofβ-catenin (S33Y) impaired themor-
phological development of neurons (Fig. 3B), showing a shorter axon
(185±15 μm) compared to control pCDNA3 nucleofected neurons
(270±15 μm). In addition, our data indicated that neither the expres-
sion of β-catenin wt nor that of β-catenin S33Y contributes to recuper-
ate the negative effect on the axonal length of the ICI treated neuronsAkt
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when compared with 320±16 μm or 185±15 μm, respectively,
pb0.005)(Fig. 3A, B).
Thus, these results indicate that additional active-β-catenin is not
sufﬁcient to eliminate the negative effects of ER antagonism on axo-
nal length.
3.4. Oestradiol activates the mTORC1 pathway in hippocampal neurons
Having initially focused on β-catenin, we next analyzed another
important route controlled by Akt activity, the mTORC1 pathway. In-
deed, it was recently reported that inhibition of the mTORC1 complex
with rapamycin impedes correct axon formation [17,37,38]. We ﬁrst
determined whether oestradiol activates the mTORC1 pathway in
hippocampal neurons by examining the activation of its direct substrate,
S6K1 [39], through its effect upon the S6 protein. The presence of
oestradiol was correlated with an increase in PS235/236-S6 which was
strongly abolished by the oestrogen receptor antagonist ICI (Fig. 4A).
This inhibition correlated with inability to elongate an axon along the
time assayed (Fig. 4B, C).
To test whether the S6 protein is phosphorylated at residues
Ser235/Ser236 in neurons by oestradiol-dependent mTORC1 activity,
cells were treated with rapamycin (an inhibitor of mTORC1) be-
fore adding oestradiol. Our data showed a substantial decrease
of PS235/236-S6 in hippocampal neurons either in the absence or
the presence of oestradiol (Fig. 4E). In addition, oestradiol could not over-
ride the effect of rapamycin in hippocampal neurons. Axons remainedshorter in the presence of rapamycin (134±8 μm versus 155±7 μm in
control neurons), and 50 nMoestradiol treatment did not recover the ax-
onal length to control levels (140±8 μm), while oestradiol treatment in
the absence of rapamycin did promoted axonal length (179±11 μm;
Fig. 4D, E).
3.5. Constitutively active Rheb (RhebQ64L) partially prevents the blocking
effect induced by ICI 182,780
To determinewhether some element in themTORC1 pathway could
participate in the effects of oestradiol on neuronal morphological, we
expressed different components of this pathway to minimise or other-
wise modify the negative effect of ICI on axon outgrowth.
First, we introduced the active mutant version of Rheb protein
(pRhebQ64L) [40] into neurons and exposed them to ICI (Fig. 5). Rheb ac-
tivates themTORC1 complex through its GTPase activity [41,42]. As an in-
ternal control neuronal cells were transfected with pRhebQ64L, and this
construct increased S6K activity as inferred from the P-S6 levels (Fig. 5C,
left panel). The expression of RhebQ64L in neurons preserved the length
of axons (192.7±8 μm) when compared to those neurons transfected
with the empty vector pCDNA3.1 (193±9.8 μm; Fig. 5A, B). However,
the expression of RhebQ64L increased neuronal complexity when we
analysed a combination of axonal ramiﬁcations, number of dendrites
and dendritic length (Supplementary Fig. 2).
Moreover, when neurons with high levels of activated Rheb
(GFP-positives) were treated with ICI, their axons branched and
elongated more than the neurons that received the empty vector
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sents the ratio of pS235/236-S6 versus total S6, which shows an increment of S6 phosphorylation mediated by oestradiol, being prevented by the presence of ICI. Data represent the
mean±s.e.m. of 3 independent experiments, *pb0.05. (B–C) Neurons were untreated (control), or treated with oestradiol (E), rapamycin or oestradiol (E) plus ICI for 3 or 7 days,
and after that neurons were ﬁxed (B, C). The immunoﬂuorescence (green: axonal marker tau-1; red: MAP2) shows the reduction in axonal length in ICI treated neurons, and the
absence of recovery by the daily addition of oestradiol (B, C). The axonal length was determined and the data represent the mean±s.e.m. of 3 independent experiments, ***pb0.001
(C). (D) Neurons were untreated (C), or treated with oestradiol, rapamycin or oestradiol plus rapamycin for 3 days and then were ﬁxed. The axonal length was quantiﬁed in each
experimental condition. The immunoﬂuorescence (acetylated-α-tubulin, green; Phalloidin, red) shows the reduction in axonal length in rapamycin treated neurons and the ab-
sence of recovery by the daily addition of oestradiol. The graph represents the mean axonal length±s.e.m. from 3 independent experiments (n=100 neurons) (**pb0.005,
***pb0.001). The data shows no statistical difference between rapamycin and rapamycin+oestradiol treatment. (E) Neurons were untreated (control), or treated with oestradiol
(E), rapamycin or oestradiol plus rapamycin for 3 days. Total neuronal extracts were collected and analysed by Western-blot using antibodies against S6 and pS235/236-S6. Actin was
used as a loading control. The increase of pS235/236-S6 provoked by oestradiol (50 nM) can be blocked by the addition of rapamycin (20 nM), and it is not reversed by the addition of
oestradiol.
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ment, neuronal morphology complexity was signiﬁcantly higher
in GFP-positive neurons expressing RhebQ64L compared to mock
transfected-GFP-positive neurons, as determined by the number of
axonal ramiﬁcations and dendritic length (Supplementary Fig. 2).
We measured the length of the axon emitted by these neurons, and
the RhebQ64L-expressing neurons experienced a partial but signiﬁcant
recovery in axonal length in the presence of ICI (131.1±7.2 μm versus71.8±3.7 μm in ICI treated pcDNA3.1 nucleofected neurons, pb0.001;
Fig. 5B).
By contrast, rapamycin blocked axonal growth notably in neurons ex-
pressing RhebQ64L (Supplementary Fig. 1), in perfect correlation with
the blockage of mTORC1 activation observed in cell extracts (data not
shown). To assess whether Rheb expression can rescue ICI effects
acting downstream, we examined its capacity to restore the levels
of phospho-S235/236 S6 in the presence of ICI. As a control, we
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since this is an antagonist of mTORC1 and therefore, its effects are inde-
pendent of Rheb over-expression.
Consequently rapamycin, independent of the RhebQ64L expres-
sion, manifested a high capacity to reduce the phosphorylation level
of PS235/236-S6 (Fig. 5C), whereas RhebQ64L expression partially recov-
ered the level of S6 phosphorylation in ICI treated neurons (Fig. 5C), aspreviously shown (Fig. 4A). This recovery correlatedwith the partial re-
covery of the axonal length (Fig. 5B, C).
3.6. Axonal elongation driven by S6K1 even in the presence of ICI
Since RhebQ64L partially recovered axonal elongation in neurons
even when the ER is blocked, we tried to identify whether a direct
1059O. Varea et al. / Biochimica et Biophysica Acta 1833 (2013) 1052–1064target of mTORC1 activation, such as S6K1, might be involved in
oestradiol-induced neuritogenesis. Accordingly, we introduced ei-
ther a wt S6K1 plasmid into neurons (Fig. 6); or a constitutively ac-
tive form of S6K1 (ΔC terminal, E389) (Fig. 7).
When wt S6K1 protein is expressed in control conditions the mor-
phology of the neurons was similar to that of the controls (Fig. 6A, B),
showing a similar neuronal complexity (dendrites and axon), al-
though the number of dendrites per neuron is higher than in control
neurons (Supplementary Fig. 2) and there was a tendency to develop
a shorter axon (157.5±5 μm versus 193±9.8 μm in control neurons).
However, S6K1 over-expression was able to partially recover axonal
length in ICI treated neurons (101.6±3.2 μm, pb0.001), compared to
axonal length of control ICI treated neurons (71.8±3.7 μm; Fig. 6A, B).
Similarly, the number of axonal ramiﬁcations is still higher in ICI treated0
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compared with mock-transfected ICI-treated (*pb0.05). Even when we incubated with rapamycin the level of S6K activity is almost insensitive to mTORC1 inhibition.
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signalling pathway involving Akt, Rheb and mTORC1.
4. Discussion
We have deﬁned a role for ERs in neuronal differentiation. We either
added daily oestradiol; or we added ERs' antagonist (ICI 182,780). The
addition of oestradiol increased the axonal and dendritic lengths while
both elongations are negatively affected by ICI 182,780. However, this
negative consequence does not compromise the speciﬁcation of axonal
polarity, either after 5 or 7 days of ICI treatment neurons maintained a
tau-1 positive extension. In addition, our data demonstrates for the
ﬁrst time that oestradiol activates the Akt/Rheb/mTORC1/S6K pathway(Scheme 1). In fact, the negative effect of ER antagonist ICI is recovered,
at least in part, by an active form of Rheb; or by an active form of S6K.
In both cases, the axonal recovery correlates with the recovery of S6 ki-
nase activity as reported by S6 phosphorylation.
4.1. The role of oestrogen receptors in neuron morphology
Considering that ICI 182,780 is an antagonist of both ERα and ERβ,
our data strongly suggested an important inﬂuence in the establishment
of neuron morphology at early stages of development. Antagonism of
ERs impedes the correct elongation of both axonal and dendritic lengths.
We don't have so much information about the role of GPR-30 oestrogen
receptor in neuronal development. However ICI is not an antagonist of
TSC1/2
Rheb
mTORC1
S6K
S6
mTORC2
Akt
GSK3
β-catenin
p85
p110
P-T 308
P-S473
Neuritogenesis ER-dependent.        Gene expression
PDK1
ER
? transcription-dependentCell growth and metabolism
PI3K
Scheme 1. ER-dependent neuritogenesis (working hypothesis). This panel represents the main observations from this work in combination with previous works. Oestradiol mod-
ulates Akt activity by increasing both Ser473 and Thr308 phosphorylations. Previous data (including our observations) indicates that the activity of Akt inﬂuences the phosphoryla-
tion level of GSK3 and may contribute, at least in neurons, to the stabilisation of β-catenin. In addition the present work indicates that this Akt-activity leads to mTORC1 activation
and S6K activation, as inferred from pS6. In addition the antagonism of the ER-neuritogenesis may be prevented, in part by Rheb or by S6K over-expression. We suggest that the
oestradiol-induced neuritogenesis is mediated by a pathway mTORC1–S6K1 dependent, at least in part. Whereas the data from “Rheb-constitutive active” may suggest a comple-
mentary pathway, still to be deﬁne, in summary we propose that this Akt–mTORC1–S6K pathway is an essential contribution to the oestradiol-dependent neuritogenic activity in
neurons, that would be complemented by the genomic action, transcription-dependent.
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compound. Nevertheless, GPR-30 may fulﬁl an important role in neuro-
nal physiology [43]. There is increasing evidence that GPR-30 is involved
in oestrogen-dependent processes in adult neurons [43,44], making it a
good candidate tomediate oestradiol-dependent plasticity at later stages.
Muchwork is needed to clarify the role of this GPR-30membrane-bound
oestrogen receptor in neurotogenesis/axonogenesis.
In contrast, in vivo results suggest that there are no obvious neuronal
changes in the different ERα or ERβ KO mice. However, in the double
KO mice there are defects in the cortical layer organisation, and in sev-
eral learning/memory tasks [45]. This discrepancy between the in vivo
versus the cell culture approach could be explained by redundant ac-
tions during development. In cell culture experiments, neuronal viability
is maintained by growth factors, such as insulin, in serum-freemedium.
Our data show that the daily addition of oestradiol causes a modest but
signiﬁcant increase in axonal length. In our opinion, the effect of
oestradiol is partially masked by the presence of Insulin/IGF-1 having
complementary functions [9]. Consequently, we decided to block the
activity of ERswith an ER antagonist, ICI 182,780, which severely affects
neuronal morphology without altering cell viability.
Obviously,we cannot discard thepossibility that in other neurotrophic
context, theﬁnal activity of the signals ER-mediatedwould be different. In
fact, it has been described that the expression of ERα in itself partly in-
hibits NGF-induced neuronal differentiation of PC12 cells. Precisely, in
the absence of 17βE2, ERα reduces NGF-induced neurite outgrowth and
NGF-induced expression of neuronal markers [46]. However in the case
of IGF-1 a cooperative effect has been reported [9,47–49].4.2. Signalling mediated by oestradiol involving PI3K–Akt activity
It is well known that oestradiol activates Akt in neurons through
the Insulin/IGF-1 receptor and ERs interact with PI3K [9,10,29,47].
This interaction of IGF-1 receptor and ERs has been described in dif-
ferent cellular systems, i.e. [48,49]. Besides, it is well known that Akt
can be activated by the phosphorylation of Thr308, mediated by PDK1,
or Ser473 mediated by the mTORC2 complex [50]. Our data show that
the activation of Akt by oestradiol occurs at both residues. Importantly,
when we block pharmacologically the activity of PI3K, axonogenesis is
prevented and this effect cannot be overcome by the addition of
oestradiol. Thus, considering the central role of PI3K in axonogenesis/
neuronal polarity, and considering the interaction between ER and the
p85 subunit of class I PI3K [28], we may suggest that the synergistic ef-
fect of oestradiol on the IGFR–PI3K/Akt pathway needs compulsorily
this lipid kinase activity [9,10,29,47]. Thus, we focused our study on
the identiﬁcation of the pathway/s used during oestradiol-mediated
neuritogenesis. Whereas the ERα isoform seems to be directly linked
or associatedwith class I PI3K [28,51], there is strong evidence of a func-
tional interaction between ERβ and this signalling pathway.
We initially analysed the pathway mediated by Akt involving GSK3
and β-catenin. One of the main targets of GSK3 is β-catenin, which is
implicated in transcription and protein stabilisation at the membrane
[52]. As we and others have described previously, oestradiol increases
the level of β-catenin [10], besides regulating β-catenins' nuclear
activity [30]. Thus, we assessed the possible implication of β-catenin
in the morphological effects generated by the oestrogen receptor, by
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β-catenin and wt β-catenin), both in control conditions and when the
ERs were blocked. Interestingly, the active form of β-catenin generated
shorter axons in control conditions which do not permit further inter-
pretations with respect to ER block. A previous study in PC12 cells has
shown that stabilised β-catenin decreases neuritogenesis, indepen-
dently of its transcriptional activity [53]. This strongly suggested that
higher levels of active β-catenin do not imply better neuritogenesis/
axonogenesis. In addition, the expression of β-catenin wt was able to
recover normal axonal morphology or length diminished by ICI.
In contrast, β-catenin has previously been implicated in deﬁning the
complexity of dendritic arbors in hippocampal neurons [33]. However,
the function of β-catenin associated with membrane events and den-
drites would be acquired at later times than those studied here, as
suggested previously by the relationship between β-catenin activity
and neuronal activity [33,54].
4.3. Role of Rheb–mTORC1 in axonal elongation mediated by oestradiol
Another central route regulated by Akt is the mTORC1 pathway,
which plays an essential role in regulating growth, metabolism, neurite
extension [14,17,55] or axonal regeneration [56] (see Scheme 1). More-
over, as previously indicated in the MCF-7 cell line [57], we describe an
Akt-dependent route that responds to oestradiol which activates
mTORC1 and subsequently S6K1, as inferred from pSer235/236-S6 phos-
phorylation. An important regulatory element of the mTORC1 pathway
is the Rheb protein (see Scheme 1), which fulﬁls an essential function
in axon guidance and neuronal polarity [38]. Our data show that the con-
stitutively active Rheb protein (RhebQ64L) partially rescues the inhibito-
ry effect of ICI on axonal growth. Oestradiol modulation of the Rheb
protein opens new possibilities for mechanisms affecting neuron
morphology, i.e. Rheb activity can activate PLD1 [58], activity that
may inﬂuence neurite extension [59–61]. This partial rescue even
suggests that complementary pathways may be implicated in the
oestradiol-mediated neuritogenesis/axonogenesis process, such as
those triggered by oestrogen membrane receptor GRP30 [43,44].
The TSC1/TSC2 complex is also a target for Rheb activity, and it de-
termines the activity of the mTORC1 complex. Mutations in their reg-
ulatory sites cause tuberous sclerosis, a syndrome that course with
mental retardation and neural hypertrophy [62]. A role has recently
been described for the inhibition of the mTORC1 complex in axonal
regeneration and in axonal speciﬁcation [17,56]. The main target for
this complex is the S6K1 protein, which activates the ribosomal S6
protein among others (for review see i.e. [63]. Indeed, local protein
synthesis is induced by mTORC1 activation in dendrites [64] and the
global increase in protein is necessary for neurite elongation during
neuron development [65]. When we tested whether the inhibition
of ERs hinders S6K1 activity, we were able to partially rescue both
the ICI-dependent reduction in axonal length and S6 phosphorylation
by the active version of S6K1. Our data indicate that a “neuronal atro-
phic phenotype” can be obtained either by ER inhibition or by using
interference constructs that are at least partially reversible by activa-
tion of Rheb or S6K1. In contrast, the active form of S6K impaired the
normal axonal extension, suggesting that a correct balance between
mTORC1 partners, such as S6K and others is required for a proper ax-
onal elongation.
In addition, the activity of S6K1 can modulate the nuclear function of
ERs through the phosphorylation of Ser167 in the MCF-7 cell line [66].
Should similar regulation of ERs occur in neurons?.This could be a second
level at which these two pathways interact after the non-genomic inﬂu-
ence of the ER over S6K. It is important to remember how the different ER
functions can modulate gene expression directly by binding to speciﬁc
DNA sequences and/or by interacting with other intracellular pathways.
There is little information regarding the transcription factors directly in-
volved in axonal elongation, and themain factors characterised are CREB,
NFAT andmore recently, SnoN [67]. Although oestradiol-dependent genetranscription might have an important implication for neuronal mor-
phology, there is evidence that gene-independent functions of ERs affect
neuronal plasticity [20].
Obviously, we cannot rule out the possibility that other pathways
may complement this oestradiol signalling. Some data have revealed
the capacity of ERs tomodulate actin dynamics [68]. Taking into account
the relevance of cytoskeleton dynamics in neuritogenesis [69,70], these
events seem of particular interest for future studies. Moreover, it has
been reported that oestradiol may induced cell migration and invasion
in breast cancer cells, regulating actin polymerisation through FAK and
N-WASP activation [71,72]. Oestradiol-activated pathways may also
modulate the translation of proteins through 4EBP1 phosphorylation
[73]. In our system, we did not determinewhether 4EBP1 phosphoryla-
tion is dependent on the ERα or ERβ. Interestingly, some proteins di-
rectly associated with neuronal polarity, such as tau, CRMP2 [37] or
Rap1b [17] have been described translationally regulated by Rheb–
mTORC1 activation.5. Conclusions
In summary, we have described for the ﬁrst time the effect of the
oestrogen receptor in early neuronal development. We found that
oestradiol activates Akt, aswell asmTORC1 complex and the S6K1 kinase,
in hippocampal neurons. We describe a role for Rheb and S6K1 bywhich
oestradiol inﬂuences neuronal morphology. The implication of the
mTORC1 pathway in the morphological effect of ERs represents another
point of interaction between growth factors and oestrogens. The ensem-
ble of our data demonstrates that the Akt–Rheb–mTORC1–S6K1pathway
plays a determinant role in oestrogen receptor-mediated neuronal
differentiation.
Supplementary data to this article can be found online at http://
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